MSH reports grants from Movember and Prostate Cancer Foundation of Australia that supported this Correspondence; personal fees from Janssen, Mundipharma, Astellas, Merck Sharp & Dohme, and AstraZeneca, all unrelated to this Correspondence; and research support from Endocyte and Advanced Accelerator Applications (a Novartis Company), unrelated to this Correspondence. SS reports grants from Novartis/AAA, AstraZeneca, Merck Sharp & Dohme, and Genetech; and personal fees from Astra Zeneca, Merck Sharp & Dohme, Bristol Myer Squibb, and AstraZeneca, unrelated to this Correspondence. IDD reports institutional payments to support prostate cancer trials from Pfizer, Bayer, Astellas, Janssen, Movember Foundation, and Merck Sharp & Dohme, all unrelated to this Correspondence. LE reports personal fees from AstraZenca, Janssen, and Astellas, unrelated this Correspondence. RJF declares no competing interests.